• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIOVENTUS LLC. DUROLANE; ACID, HYALURONIC, INTRAARTICULAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIOVENTUS LLC. DUROLANE; ACID, HYALURONIC, INTRAARTICULAR Back to Search Results
Lot Number 20044
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Pain (1994); Inadequate Pain Relief (2388)
Event Date 05/09/2022
Event Type  Injury  
Event Description
Pain in knees started approximately 8 hours after receiving injections.Started off worse in the right knee but now the pain is worse in the left.No reported swelling or bruising.Pt contacted mdo on (b)(6) 2022 and received a call back around 1 pm.Pt was instructed to take ibuprofen and that to call the mdo back if the pain has not gotten better in 2 days.The pt has not had any alleviation in the pain.Pt also has difficulty bending the knees due to increased pain.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
DUROLANE
Type of Device
ACID, HYALURONIC, INTRAARTICULAR
Manufacturer (Section D)
BIOVENTUS LLC.
MDR Report Key14430461
MDR Text Key292046837
Report NumberMW5109770
Device Sequence Number1
Product Code MOZ
UDI-Device Identifier89130202001
UDI-Public89130-2020-01
Combination Product (y/n)Y
Reporter Country CodeUS
Number of Events Reported1
Summary Report (Y/N)N
Report Source Voluntary
Reporter Occupation Nurse
Type of Report Initial
Report Date 05/13/2022
2 Devices were Involved in the Event: 1   2  
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Lot Number20044
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received Not provided
Initial Date FDA Received05/17/2022
Patient Sequence Number1
Treatment
ACETAMINOPHEN; ALBUTEROL SULFATE NEBULIZED SOLUTION; ALFUZOSIN ; ATORVASTATIN ; DICLOFENAC; FERROUS SULFATE; FEXOFENADINE; FLUTICASONE; FOLIC ACID; GABAPENTIN ; GLIPIZIDE; HYDROCHLOROTHIAZIDE; LORATIDINE; LOSARTAN ; MELATONIN ; METFORMIN ; NAPROXEN ; NITROGLYCERIN SUBLINGUAL; OMEPRAZOLE; SENNA
Patient Outcome(s) Other;
Patient Age57 YR
Patient SexMale
Patient Weight70 KG
Patient EthnicityNon Hispanic
Patient RaceAsian
-
-